Capecitabine Tablet, Film Coated
Product Images NDC 82511-002

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 82511-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teyro Labs Private Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Capecitabine Tablets, Usp 150 mg (NDC 82511-001-15)

Capecitabine Tablets, Usp 150 mg (NDC 82511-001-15)
Capecitabine Tablets, USP 150 mg film-coated tablets packaging label from Teyro Labs Private Limited. The carton displays the product name, strength, quantity of 60 tablets, and warnings indicating it is a hazardous drug. Instructions include swallowing tablets whole and storage conditions between 20° to 25°C, with excursions permitted to 15° to 30°C. Barcode and manufacturer details are also present.*
FDA Label Image

Capecitabine Tablets, Usp 150 mg (NDC 82511-001-15)

Capecitabine Tablets, Usp 150 mg (NDC 82511-001-15)
Label for Capecitabine tablets, USP, 150 mg film-coated tablets. The label shows the product name, strength, the labeler Teyro Labs Private Limited, and a quantity of 60 tablets. It includes storage instructions (20° to 25°C), a warning that the drug is hazardous and prescription-only, and advises against crushing or cutting tablets. The label also features a barcode and manufacturing information including license number and location in Tamil Nadu, India.*
FDA Label Image

Capecitabine Tablets, Usp 500 mg (NDC 82511-002-50)

Capecitabine Tablets, Usp 500 mg (NDC 82511-002-50)
Packaging label for Capecitabine Tablets, USP 500 mg film-coated tablets by Teyro Labs Private Limited. The carton holds 120 tablets for oral use. The label includes storage instructions, patient directions to swallow whole with water within 30 minutes of a meal, and a warning that it is a hazardous drug. Manufactured in India with lot and expiration details on the box.*
FDA Label Image

Capecitabine Tablets, Usp 500 mg (NDC 82511-002-50)

Capecitabine Tablets, Usp 500 mg (NDC 82511-002-50)
Capecitabine Tablets, USP 500 mg film-coated oral tablets packaging label by Teyro Labs Private Limited. The label includes the NDC 82511-002-50, a quantity of 120 tablets, and a warning indicating it is a hazardous drug for prescription use only. Storage instructions and manufacturer details from Tamil Nadu, India, are also visible.*
FDA Label Image

Figure 1 (Capecitabine Tablets Usp Figure 1)

Figure 1 (Capecitabine Tablets Usp Figure 1)
A survival curve chart comparing treatment groups over months since randomization. The x-axis shows months from 0 to 96, and the y-axis shows survival probability from 0.3 to 1.0. Two curves are plotted: a dashed line for 5-FU + Leucovorin and a solid line for Capecitabine, showing survival trends over time with patient counts at risk listed below.*
FDA Label Image

Figure 2 (Capecitabine Tablets Usp Figure 2)

Figure 2 (Capecitabine Tablets Usp Figure 2)
A survival curve graph comparing two treatment groups: 5-FU plus leucovorin (dashed line) and capecitabine (solid line). The y-axis represents survival probability ranging from 0 to 1.0, and the x-axis shows months since randomization from 0 to 96. Below the graph, a table displays the number of patients at risk for each group at various time points.*
FDA Label Image

Figure 3 (Capecitabine Tablets Usp Figure 3)

Figure 3 (Capecitabine Tablets Usp Figure 3)
A Kaplan-Meier survival curve comparing estimated probability over time in days between two treatment groups: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent.*
FDA Label Image

Figure 4 (Capecitabine Tablets Usp Figure 4)

Figure 4 (Capecitabine Tablets Usp Figure 4)
A Kaplan-Meier survival curve comparing estimated probabilities over time in days for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The graph includes probability on the vertical axis and time (days) on the horizontal axis with annotated median survival times.*
FDA Label Image

Figure 5 (Capecitabine Tablets Usp Figure 5)

Figure 5 (Capecitabine Tablets Usp Figure 5)
A Kaplan-Meier survival curve graph showing estimated probability over time (days) comparing two treatment groups: one receiving Docetaxel 100 mg/sqm every 3 weeks, and the other receiving intermittent Capecitabine 1250 mg/sqm twice daily with Docetaxel 75 mg/sqm every 3 weeks. The graph includes markers indicating median survival times for each group.*
FDA Label Image

Chemical Structure (Capecitabine Tablets Usp Structure)

Chemical Structure (Capecitabine Tablets Usp Structure)
Chemical structure diagram of capecitabine, the active ingredient in the Capecitabine oral film-coated tablet by Teyro Labs Private Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.